Canagliflozin : A New Hope in the Antidiabetic Armamentarium

Title:Canagliflozin : A New Hope in the Antidiabetic Armamentarium

Volume: 8 Issue: 3

Author(s): Vasiliki K. Katsi, Christos A. Michalakeas, Charalambos E. Grassos, Georgia D. Vamvakou, John P. Lekakis, Dimitris Tousoulis, Christodoulos I. Stefanadis, Thomas K. Makris and Ioannis E. Kallikazaros

Affiliation:

Keywords: Anti-diabetics, canagliflozin, hyperglycemia, invokana, sodium-glucose cotransporter-2 (SGLT2) inhibitors, type 2 diabetes mellitus.

Abstract: Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus.

Cite this article as:

Katsi K. Vasiliki, Michalakeas A. Christos, Grassos E. Charalambos, Vamvakou D. Georgia, Lekakis P. John, Tousoulis Dimitris, Stefanadis I. Christodoulos, Makris K. Thomas and Kallikazaros E. Ioannis, Canagliflozin : A New Hope in the Antidiabetic Armamentarium, Recent Patents on Cardiovascular Drug Discovery 2013; 8 (3) . https://dx.doi.org/10.2174/1574890108666131213100613

DOI https://dx.doi.org/10.2174/1574890108666131213100613	Print ISSN 2212-3962
Publisher Name Bentham Science Publisher	Online ISSN 1574-8901